Feed MIRM
MI

Mirum Pharmaceuticals, Inc. MIRM · NASDAQ

$80.14 -2.73% (-$2.25)

Summary

33 / 100 · Bulios Score

What speaks for it

  • Revenue grew by 89% a year over the last 3 years.
  • Analysts expect revenue to grow by 34% this fiscal year.

What to watch

  • The company made a loss over the last 12 months.
  • It passes only 3 of the 9 points of the Piotroski financial health test.
  • It missed profit estimates 4 times in the last 8 quarters.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced
Bulios Fair Price
Current price $80.14

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 89% a year over the last 3 years. For the next fiscal year analysts expect revenue to grow by 34%.

Growth in detail

Does it make money?

Poorly

Over the last 12 months it made a loss of $860.2M.

Profitability in detail

Is it financially healthy?

Debt is a burden

Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $151.2 is 89% above today's price. 100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

Product brings in 100% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.